« Return to News | CROs/Service Providers

GVK Bioscience’s Ahmedabad clinical pharmacology unit clears FDA audit

Monday, July 30, 2012 09:52 AM

GVK Biosciences, an Asian CRO, announced that its Ahmedabad Clinical Pharmacology Unit has successfully cleared an FDA audit with zero 483s/observations from the agency. FDA visited and audited a First-to-File study for one of GVK BIO’s customers.

The GVK Ahmedabad facility, commissioned in 2010, has three clinics with 110 beds. The facility has been inspected and approved by drugs controller general of India, Anvisa-Brazil and Ministry of Health (MoH)-Turkey. The Ahmedabad facility carries out bioavailability and bioequivalence (BA/BE) studies that are submitted to various regulatory agencies including FDA, TGA (Australia), European Regulatory agencies, Health Canada, Anvisa-Brazil and MoH (Turkey).

“This is a clear testimony of the high standards of quality and processes followed at GVK BIO,” said Manni Kantipudi, CEO of GVK. “The sponsor can now carry out BA/BE studies at either of our sites—Ahmedabad or Hyderabad—with a wider choice of population and capacities”.

The Ahmedabad success comes on the heels of regulatory joint inspection by FDA, ANSM (France), AGES (Austria) and WHO, of the GVK Hyderabad facility. This inspection was the first joint inspection of a CRO by the four agencies. GVK received zero 483s by FDA in this joint inspection as well. The GVK BIO Hyderabad facility is a full service provider of BA/BE services with four clinics and 144 beds supported by a bioanalytical facility with 16 LC-MS/MS machines.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.